Terbutaline modified-release - Vectura

Drug Profile

Terbutaline modified-release - Vectura

Alternative Names: SKP-1052

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SkyePharma PLC
  • Developer Vectura
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Small molecules; Tocolytics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Hypoglycaemia

Highest Development Phases

  • Phase I Hypoglycaemia

Most Recent Events

  • 08 Sep 2016 Terbutaline modified-release is still in phase I development for Hypoglycaemia (Prevention) (Skyepharma Pipeline, September 2016)
  • 02 Sep 2011 Terbutaline modified-release - Skye Pharma is available for licensing as of 02 Sep 2011.
  • 22 Feb 2011 Phase-I clinical trials in Hypoglycaemia (prevention) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top